Sajith Wickramasekara, Benchling CEO

Bench­ling adds an­oth­er megaround in­to the fold, look­ing even more uni­corn-y as a pos­si­ble IPO ap­proach­es

Tout­ing its mis­sion to rev­o­lu­tion­ize R&D by bring­ing drug de­vel­op­ment in­to the cloud, Bench­ling has earned its uni­corn horn from in­vestors hun­gry for some­thing new. A new round of fi­nanc­ing will now dri­ve that eye-pop­ping val­u­a­tion even high­er.

Just sev­en months af­ter rais­ing $200 mil­lion from in­vestors in a Se­ries E, valu­ing the R&D cloud soft­ware de­vel­op­er at just over $4 bil­lion in April, Bench­ling raised $100 mil­lion in a Se­ries F round, valu­ing the com­pa­ny at a tidy $6.1 bil­lion. And this doesn’t take in­to con­sid­er­a­tion that Bench­ling was worth un­der $1 bil­lion last April, ac­cord­ing to Forbes — just af­ter the Covid-19 pan­dem­ic hit the world stage.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.